3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Conditions
Neoplasm Metastasis
2
Urogenital Neoplasms
1
Solitary Fibrous Tumors
1
Sarcoma
1
Prostatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Lung Neoplasms
1
Granuloma, Plasma Cell
1
Glioma
1
Glioblastoma
1
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Suspensions
×
1 year
×
Clear all
NCT04060628
2026-01-23
Expanded Access to NanoDoce
NanOlogy, LLC
No longer available